I'm sorry to hear about your health challenges. Here is some information about CAR-T cell therapy for multiple myeloma:

- Eligibility: CAR-T cell therapy is for those whose myeloma is refractory (resistant to treatment) or relapsed (came back after treatment). You must have tried at least four other treatments, including read more

I'm sorry to hear about your health challenges. Here is some information about CAR-T cell therapy for multiple myeloma:

- Eligibility: CAR-T cell therapy is for those whose myeloma is refractory (resistant to treatment) or relapsed (came back after treatment). You must have tried at least four other treatments, including immunomodulatory drugs (like Revlimid), proteasome inhibitors (like Velcade), and monoclonal antibodies.

- Treatment Process: CAR-T cells are engineered to recognize and kill cancer cells. They target a protein called BCMA on cancerous plasma cells. The approved CAR-T cell treatment for multiple myeloma is called Abecma (idecabtagene vicleucel).

- Hospital Stay: After receiving CAR-T cell infusion, a hospital stay of several weeks is often required to monitor the treatment's effectiveness and manage side effects. Even after discharge, staying close to the treatment center for a month or more may be necessary in case of complications.

- Effectiveness: Studies show that 28% of people achieved complete response with idecabtagene vicleucel, and 65% of those maintained the response for at least 12 months.

Wishing you the best with your upcoming pacemaker procedure and continued strength in your treatment journey.

 This AI-generated response comes from MyMyelomaTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

CAR-T Cell Therapy for Multiple Myeloma: What Is It? | MyMyelomaTeam

Treatments for Myeloma | MyMyelomaTeam